TRIEU VUONG (CEO and Chairman of the Board) purchased 0.5% of their position (500K shares) of ONCOTELIC THERAPEUTICS, INC. on the open market
Open‑market purchase worth $10.9K — a small addition. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 6/30/2023ACC: 0001493152-23-023015
DirectorOfficer10% Owner· CEO and Chairman of the Board
Since Apr 2019
+500K
Net shares
Net buyer
$10.9K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
500K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+75K
Price / share
$0.03
Trade value
$1.95K
% of position
0.1%
6/28/2023
91.54M→91.62M
Common Stock
Direct
Shares
+425K
Price / share
$0.02
Trade value
$8.93K
% of position
0.5%
6/29/2023
91.62M→92.04M
Total
Net shares
+500K
Net value
$10.88K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/28/2023 | P · Purchase | +75K | $0.03 | $1.95K | 0.1% | 91.54M | 91.62M |
| Common Stock Direct | 6/29/2023 | P · Purchase | +425K | $0.02 | $8.93K | 0.5% | 91.62M | 92.04M |
| Total | +500K | $10.88K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned6.87M
Common Stock
IndirectShares owned16.78M
Total
23.65M indirect23.65M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 6.87M | Indirect |
| Common Stock | 16.78M | Indirect |
| Total | 23.65M | 23.65M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported